Integra LifeSciences Holdings Co. (NASDAQ:IART) Short Interest Down 6.1% in January

Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) was the target of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 3,240,000 shares, a drop of 6.1% from the December 31st total of 3,450,000 shares. Based on an average trading volume of 786,000 shares, the short-interest ratio is presently 4.1 days. Approximately 4.9% of the shares of the company are sold short.

Insider Transactions at Integra LifeSciences

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the company's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the completion of the transaction, the executive vice president now owns 56,182 shares in the company, valued at approximately $1,357,357.12. This represents a 2.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.10% of the company's stock.

Institutional Investors Weigh In On Integra LifeSciences

Several institutional investors and hedge funds have recently modified their holdings of IART. Principal Financial Group Inc. lifted its position in shares of Integra LifeSciences by 18.7% during the third quarter. Principal Financial Group Inc. now owns 401,432 shares of the life sciences company's stock worth $7,294,000 after purchasing an additional 63,266 shares in the last quarter. Versor Investments LP purchased a new position in Integra LifeSciences in the 3rd quarter valued at about $612,000. BNP Paribas Financial Markets grew its stake in shares of Integra LifeSciences by 824.5% during the third quarter. BNP Paribas Financial Markets now owns 111,775 shares of the life sciences company's stock valued at $2,031,000 after acquiring an additional 99,685 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Integra LifeSciences during the third quarter worth about $960,000. Finally, State of Alaska Department of Revenue lifted its stake in shares of Integra LifeSciences by 144.3% in the third quarter. State of Alaska Department of Revenue now owns 131,751 shares of the life sciences company's stock worth $2,393,000 after acquiring an additional 77,825 shares in the last quarter. Hedge funds and other institutional investors own 84.78% of the company's stock.

Analyst Ratings Changes

Several analysts recently commented on IART shares. Morgan Stanley assumed coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They issued an "underweight" rating and a $20.00 price objective for the company. Truist Financial lowered their target price on Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating on the stock in a report on Monday, October 14th. Finally, Citigroup lifted their target price on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a research note on Tuesday, November 5th. Three analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $23.00.

Integra LifeSciences Trading Up 1.9 %

Shares of NASDAQ IART traded up $0.50 during trading on Wednesday, hitting $26.55. 371,536 shares of the company traded hands, compared to its average volume of 548,754. The firm has a market capitalization of $2.05 billion, a P/E ratio of -294.97, a P/E/G ratio of 0.87 and a beta of 1.17. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The company has a 50-day moving average price of $23.73 and a 200-day moving average price of $22.04. Integra LifeSciences has a 1 year low of $16.81 and a 1 year high of $45.42.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company had revenue of $380.80 million during the quarter, compared to analyst estimates of $375.81 million. During the same period in the prior year, the firm posted $0.76 earnings per share. The firm's revenue was down .4% on a year-over-year basis. On average, equities analysts predict that Integra LifeSciences will post 2.45 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.